109: Aurobindo's US outlook improves but earnings may just be steady

Investors are banking on Aurobindo’s US pharma revenues getting a boost on the back of improving injectable sales in the second quarter. But a part of that growth already seems to be reflecting in the stock price gains of about 86% in 2020. Find more details in this podcast. Listen in.

132 Episodes

21 Dec 2024

92: Embassy’s robust rental collections reflect resilience of high-end office properties

5 MINS

21 Dec 2024

91: Why Mazagon Dock’s IPO has piqued retail investor interest

6 MINS

21 Dec 2024

90: Comatose Lakshmi Vilas Bank needs a quick RBI prescription.

6 MINS

21 Dec 2024

89: Accenture’s healthy order wins underpins the optimism in IT stocks

6 MINS

21 Dec 2024

88: Jio, flush with capital, turns up the heat on Airtel, Voda-Idea

6 MINS

21 Dec 2024

87: With CAMS IPO, investors get a unique play on India’s mutual fund industry

5 MINS

21 Dec 2024

86: Despite near decade-low yields, RBI may need to binge on bonds

5 MINS

21 Dec 2024

85: Apollo Hospitals’ recovery from covid is encouraging, but its stock is pricey

6 MINS

21 Dec 2024

84: Investor hopes from Indian IT rise after HCL Tech’s earnings update

6 MINS

21 Dec 2024

83: Sales recover at Tata Motors, but skepticism runs deep for investors.

6 MINS

< 1 … 3 4 5 6 7 … 14 >